Web Results

thorax.bmj.com/content/71/8/675

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease that ... Notably, repositioning of drugs can shorten drug development time by >50% as ...

www.verywellhealth.com/research-advances-in-idiopathic-pulmonary-fibrosis-4147729

4 These genetic markers are providing researchers with specific targets for drug development in the treatment of IPF. In a few years, drugs specifically “tailored” to  ...

www.mayoclinic.org/medical-professionals/pulmonary-medicine/news/anti-fibrotic-therapy-in-the-treatment-of-ipf-ongoing-concerns-and-current-practices/mac-20438808

As both medications are intended to slow disease progression, perhaps measured over months or years, drug adherence remains an important issue, particularly ...

liminalbiosciences.com/pipeline/pbi-4050/idiopathic-pulmonary-fibrosis-drug-development-overview

Orphan drug development for IPF: In January 2017, we completed an open-label, single arm, exploratory, observational Phase 2 trial of fezagepras, both as a ...

rtmagazine.com/products-treatment/pharmaceuticals/pulmonary-fibrosis-drug-development-pipeline-launched

Oct 10, 2019 ... The PF Foundation has launched a new PF Drug Development Pipeline tool to help the pulmonary fibrosis community search for different ...

www.globenewswire.com/news-release/2019/04/25/1809831/0/en/Global-Idiopathic-Pulmonary-Fibrosis-Competitive-Landscape-Report-2019-2026-132-Drugs-Spanning-All-Stages-of-Development-with-Approximately-2-3-of-the-Drugs-in-the-Preclinical-Stag.html

Apr 25, 2019 ... The IPF pipeline consists of 132 drugs spanning all stages of development with approximately two-third of the drugs in the preclinical stage.

www.therapeutaix.com/drug-development-in-ipf

Dec 1, 2020 ... Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging and we discuss these challenges and the opportunities in our ...

www.fda.gov/media/91396/download

for IPF. FDA will carefully consider this input as it fulfills its role in the drug development process, including when advising sponsors on their drug development ...

emedicine.medscape.com/article/301226-medication

Jul 15, 2019 ... Nintedanib was associated with the development of diarrhea; however, it led to discontinuation of the medication in less than 5% of the patients ...

www.nature.com/articles/nrd2767.pdf?origin=ppub

capacity (VC) in Shionogi's Phase III trials. “The key challenges in drug development for IPF are to identify agents that will reverse the fibrosing disease process ...